Bortezomib, the first-in-class proteasome inhibitor, has become one of the standard
treatments in multiple myeloma. The agent is thought to exert its antimyeloma effects through …

Various lineages of B cells are being increasingly recognized as important players in the
etiology and prognosis of both acute and chronic graft rejection. The role of immature …

The role of donor‐specific anti‐human leukocyte antigen antibodies (DSAs) that develop
late after living donor liver transplantation is unknown. Seventy‐nine pediatric recipients …

BACKGROUND: The presence of alloantibodies in patients awaiting heart transplantation is
associated with increased waiting time to transplant, increased risk of rejection after …

Background Late antibody-mediated rejection (AMR) after heart transplantation is suspected
to be associated with a poor short-term prognosis. Methods A retrospective single-center …

Background. Antibody-mediated rejection (AMR) is an important problem after heart
transplantation. Most cases seem to occur in sensitized recipients with preformed donor …

Background. Recipient presensitization represents a major hurdle to successful renal
transplantation. Previous case series have suggested that the proteasome inhibitor …

BACKGROUND: Sensitization to human leukocyte antigen (HLA) prolongs waiting list time
and reduces allograft survival in solid organ transplantation. Current strategies for …

Although current therapies for pretransplant desensitization and treatment of antibody‐
mediated rejection (AMR) have had some success, they do not specifically deplete plasma …

Several desensitization strategies have been investigated for the reversal of acute antibody-
mediated rejection or for the removal of preformed anti-HLA antibodies, with the aim to …